HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Neil L Berinstein Selected Research

Therapeutics

1/2018IRX-2 natural cytokine biologic for immunotherapy in patients with head and neck cancers.
1/2016Anti-PD-1 increases the clonality and activity of tumor infiltrating antigen specific T cells induced by a potent immune therapy consisting of vaccine and metronomic cyclophosphamide.
1/2014Metronomic cyclophosphamide enhances HPV16E7 peptide vaccine induced antigen-specific and cytotoxic T-cell mediated antitumor immune response.
6/2012A short course of neoadjuvant IRX-2 induces changes in peripheral blood lymphocyte subsets of patients with head and neck squamous cell carcinoma.
10/2011Peptide Based Vaccine Approaches for Cancer-A Novel Approach Using a WT-1 Synthetic Long Peptide and the IRX-2 Immunomodulatory Regimen.
10/2010Preclinical qualification of a new multi-antigen candidate vaccine for metastatic melanoma.
9/2009Strategies to enhance the therapeutic activity of cancer vaccines: using melanoma as a model.
8/2008Combination chemotherapy and ALVAC-CEA/B7.1 vaccine in patients with metastatic colorectal cancer.
3/2006Principles of maintenance therapy.
3/2005What is remission in follicular lymphoma and what is its relevance?
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Neil L Berinstein Research Topics

Disease

22Neoplasms (Cancer)
10/2018 - 04/2002
6Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular)
04/2018 - 11/2002
4Mantle-Cell Lymphoma (Lymphoma, Mantle Cell)
02/2004 - 02/2002
3Colorectal Neoplasms (Colorectal Cancer)
10/2018 - 11/2007
3Lymphoma (Lymphomas)
06/2014 - 02/2006
3Prostatic Neoplasms (Prostate Cancer)
01/2014 - 02/2010
3Melanoma (Melanoma, Malignant)
10/2010 - 04/2008
2Head and Neck Neoplasms (Head and Neck Cancer)
01/2018 - 06/2012
2Squamous Cell Carcinoma of Head and Neck
01/2018 - 06/2012
2Necrosis
01/2018 - 06/2012
2Fibrosis (Cirrhosis)
01/2018 - 06/2012
2Injection Site Reaction
01/2014 - 08/2012
2Squamous Cell Neoplasms (Squamous Cell Cancer)
06/2012 - 06/2012
2Carcinogenesis
10/2011 - 04/2002
2Breast Neoplasms (Breast Cancer)
02/2010 - 08/2005
2Tetanus
08/2008 - 02/2006
2Disease Progression
08/2008 - 05/2003
2Non-Hodgkin Lymphoma (Lymphosarcoma)
03/2006 - 11/2002
1Thrombocytopenia (Thrombopenia)
04/2018
1Neutropenia
04/2018
1Rubella (German Measles)
04/2018
1Ovarian Neoplasms (Ovarian Cancer)
08/2015
1Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse)
06/2014
1B-Cell Lymphoma (Lymphoma, B Cell)
06/2014
1Leiomyosarcoma
04/2008
1Neoplasm Metastasis (Metastasis)
04/2008
1Communicable Diseases (Infectious Diseases)
11/2007
1Papillary Carcinoma
08/2005
1Noninfiltrating Intraductal Carcinoma (DCIS)
08/2005
1B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
05/2003
1Graft vs Host Disease (Graft-Versus-Host Disease)
11/2002
1Residual Neoplasm
11/2002

Drug/Important Bio-Agent (IBA)

12VaccinesIBA
01/2016 - 04/2002
8AntigensIBA
01/2016 - 04/2008
7Cancer VaccinesIBA
01/2016 - 05/2003
7Peptides (Polypeptides)IBA
01/2016 - 02/2006
6IRX 2IBA
01/2018 - 10/2011
5Cyclophosphamide (Cytoxan)FDA LinkGeneric
01/2016 - 01/2014
4Monoclonal AntibodiesIBA
09/2009 - 02/2004
3Immunoglobulins (Immunoglobulin)IBA
04/2018 - 04/2002
3CytokinesIBA
01/2018 - 09/2009
3Rituximab (Mabthera)FDA Link
06/2014 - 02/2002
2Biomarkers (Surrogate Marker)IBA
10/2018 - 11/2002
2Biological ProductsIBA
01/2018 - 06/2012
2DNA (Deoxyribonucleic Acid)IBA
01/2016 - 08/2005
2Proteins (Proteins, Gene)FDA Link
01/2016 - 08/2005
22-Methyl-4-chlorophenoxyacetic Acid (MCPA)IBA
01/2016 - 01/2014
2Prednisone (Sone)FDA LinkGeneric
06/2014 - 06/2014
2Vincristine (Oncovin)FDA LinkGeneric
06/2014 - 06/2014
2DPX-0907IBA
01/2014 - 08/2012
2HLA-A2 Antigen (HLA A2 Antigen)IBA
01/2014 - 08/2012
2EpitopesIBA
10/2011 - 04/2002
1Fibronectins (Fibronectin)IBA
10/2018
1Carcinoembryonic AntigenIBA
10/2018
1ibritumomab tiuxetan (Zevalin)FDA Link
04/2018
1ChemokinesIBA
01/2018
1Chemokine ReceptorsIBA
01/2018
1Immunologic Factors (Immunomodulators)IBA
01/2016
1SurvivinIBA
08/2015
1R-CHOP protocolIBA
06/2014
1Doxorubicin (Adriamycin)FDA LinkGeneric
06/2014
1HLA Antigens (Human Leukocyte Antigens)IBA
01/2014
1Protein Subunit VaccinesIBA
01/2014
1EmulsionsIBA
08/2012
1Eosine Yellowish-(YS) (Eosin)IBA
06/2012
1Coloring Agents (Dyes)IBA
06/2012
1Hematoxylin (Haematoxylon)IBA
06/2012
1Neoplasm Antigens (Tumor Antigens)IBA
10/2011
1Estrogen Receptor alphaIBA
02/2010
1AndrogensIBA
02/2010
1GATA Transcription FactorsIBA
02/2010
1AntioxidantsIBA
02/2010
1Progesterone Receptors (Progesterone Receptor)IBA
02/2010
1Fluorouracil (Carac)FDA LinkGeneric
08/2008
1Tetanus Toxoid (Vaccine, Tetanus)FDA Link
08/2008
1Leucovorin (Folinic Acid)FDA Link
08/2008
1Irinotecan (Camptosar)FDA LinkGeneric
08/2008
1Interleukin-2 (IL2)IBA
04/2008
1Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA
04/2008
1AutoantigensIBA
11/2007
1gp100 Melanoma AntigenIBA
02/2006
1Viral VaccinesIBA
02/2006
1SYBR Green IIBA
02/2006

Therapy/Procedure

13Therapeutics
01/2018 - 02/2002
10Immunotherapy
04/2018 - 02/2002
6Drug Therapy (Chemotherapy)
06/2014 - 11/2002
4Stem Cell Transplantation
02/2006 - 02/2002
1Injections
01/2018
1Neoadjuvant Therapy
06/2012
1Combination Drug Therapy (Combination Chemotherapy)
08/2008